Breath Analysis and Arterial Stiffness in Patients With Respiratory Diseases
Launched by I.M. SECHENOV FIRST MOSCOW STATE MEDICAL UNIVERSITY · Feb 6, 2023
Trial Information
Current as of June 27, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Evaluating of eVOCs profiles by proton mass spectrometry with a time-of-flight (PTR-TOF) in patients with different chronic respiratory diseases is of great interest for assessing the prognosis and development of severe ventilation and cardiovascular disorders.
The aim of our study is to determine the diagnostic significance of PTR-TOF analysis in patients with chronic respiratory diseases and to identify specific eVOC markers of a severe ventilation and cardiovascular disorders in patients with different chronic respiratory diseases.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Written informed consent to participate in the study;
- • 2. Age 18 and over;
- • 3. Clinical diagnosis of one of chronic respiratory diseases (COPD, bronchial asthma, cystic fibrosis, lymphangioleiomyomatosis, hypersensitivity pneumonitis or other interstitial lung disease).
- Exclusion Criteria:
- • 1. Unable to sign informed consent;
- • 2. Respiratory disease (for controls);
- • 3. Mental illness (severe dementia, schizophrenia, severe depression, manic-depressive psychosis);
- • 4. Acute coronary syndrome, acute cerebrovascular accident, pulmonary embolism within the last 3 months;
- • 5. Oncology;
- • 6. Previous lung transplantation (for patients with respiratory diseases);
- • 7. Diseases and conditions that can change the ECG picture and complicate the analysis of the ECG (conduction disturbance, pacemaker);
- • 8. Inability to use a heart monitor (congenital developmental anomalies, traumatic amputation of the upper limbs, essential tremor, Parkinson's disease);
- • 9. Pregnancy.
About I.M. Sechenov First Moscow State Medical University
i.m. Sechenov First Moscow State Medical University is a prestigious institution dedicated to advancing medical education, research, and clinical practice. As a leading center for medical innovation in Russia, the university fosters a collaborative environment for scientific inquiry and the development of novel therapies. With a commitment to high-quality clinical trials, i.m. Sechenov aims to contribute significantly to the global biomedical landscape by evaluating new treatments and improving patient care through rigorous research methodologies and ethical standards.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Moscow, , Russian Federation
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials